MedPath

Polymyxin B

Generic Name
Polymyxin B
Brand Names
Casporyn HC, Cortisporin, Dioptrol, Diosporin, Diphen, Maxitrol, Neo-polycin, Neo-polycin HC, Neosporin Ointment, Neosporin Plus Maximum Strength, Neosporin Plus Maximum Strength Cream, Neosporin Solution, Polycin-B, Polysporin, Polytrim, Procomycin, Statrol, Triple Antibiotic
Drug Type
Small Molecule
Chemical Formula
C56H98N16O13
CAS Number
1404-26-8
Unique Ingredient Identifier
J2VZ07J96K
Background

Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.

Indication

Polymyxin B is indicated for the treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa.

Associated Conditions
Acute Otitis Media (AOM), Bacteremia caused by Enterobacter aerogenes, Bacterial Conjunctivitis, Bacterial Infections, Chronic Otitis Media, Escherichia urinary tract infection, Klebsiella bacteraemia, Meningitis caused by Haemophilus influenzae, Meningitis, Bacterial, Ocular Inflammation, Otitis Externa, Otorrhoea, Superficial ocular infections of the conjunctiva caused by susceptible bacteria, Superficial ocular infections of the cornea caused by susceptible bacteria, Urinary Tract Infection, Ocular bacterial infections
Associated Therapies
-
Clinical Trials
Related News

Intraventricular Administration of Intracranial Infections Caused by （Carbapenem-resistant Gram-negative Bacilli）CRGNB

Recruiting
Conditions
Intracranial Infections
Interventions
Drug: Polymyxin B
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
222
Registration Number
NCT06595979
Locations
🇨🇳

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

🇨🇳

Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China

🇨🇳

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

A Pharmacokinetic Study of Polymyxin B in Healthy Subjects and Subjects With Renal Insufficiency

Phase 1
Completed
Conditions
Antibiotic Toxicity
Interventions
Drug: Polymyxin B
First Posted Date
2022-05-04
Last Posted Date
2023-04-27
Lead Sponsor
TTY Biopharm
Target Recruit Count
22
Registration Number
NCT05359627
Locations
🇨🇳

Shin Kong Memorial Wu Ho-Su Hospital, Taipei, Taiwan

The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae

Early Phase 1
Conditions
Antibiotic Resistant Infection
Interventions
Drug: Fosfomycin
Drug: Tigecycline
Drug: Polymyxin B
First Posted Date
2019-05-15
Last Posted Date
2019-05-15
Lead Sponsor
Shanghai 10th People's Hospital
Target Recruit Count
80
Registration Number
NCT03950544
Locations
🇨🇳

Shanghai 10th people's hospital, Shanghai, Shanghai, China

Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens

Phase 3
Conditions
Resistant Infection
Trauma
Critical Illness
Interventions
Drug: Polymyxin B
First Posted Date
2017-05-18
Last Posted Date
2019-02-08
Lead Sponsor
University of Puerto Rico
Target Recruit Count
40
Registration Number
NCT03159078
Locations
🇵🇷

Trauma Hospital, San Juan, Puerto Rico

Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria

Phase 4
Conditions
Hospital Infection
Interventions
Drug: Polymyxin B
First Posted Date
2014-12-31
Last Posted Date
2015-09-01
Lead Sponsor
Mahidol University
Target Recruit Count
100
Registration Number
NCT02328183
Locations
🇹🇭

Siriraj hospital, Bangkok, Thailand

Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria

Phase 2
Withdrawn
Conditions
Bacteremia
Ventilator-associated Pneumonia
Healthcare-associated Pneumonia
Interventions
Drug: Polymyxin B + Doripenem
Drug: Polymyxin B
First Posted Date
2014-05-08
Last Posted Date
2019-10-09
Lead Sponsor
Tan Tock Seng Hospital
Registration Number
NCT02134106
Locations
🇸🇬

National University Hospital, Singapore, Singapore

🇸🇬

Singapore General Hospital, Singapore, Singapore

Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy

Phase 4
Completed
Conditions
Actinic Keratosis
Interventions
Drug: Biafine
Drug: Polysporin
First Posted Date
2008-06-12
Last Posted Date
2018-12-31
Lead Sponsor
Wake Forest University
Target Recruit Count
20
Registration Number
NCT00695578
Locations
🇺🇸

Wake Forest University Health Sciences Dermatology, Winston-Salem, North Carolina, United States

Use of Ointments in Prevention of Catheter Related Infections in PD

Phase 4
Completed
Conditions
End Stage Renal Disease
Interventions
Drug: Mupirocin ointment
Drug: Polysporin Triple
First Posted Date
2006-11-17
Last Posted Date
2015-03-18
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
200
Registration Number
NCT00400595
Locations
🇨🇦

University Health Network, Toronto, Ontario, Canada

🇨🇦

Scarborough General Hospital, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy